 VANCOUVER, British Columbia, Sept. 22, 2021 GLOBE NEWSWIRE -- BetterLife Pharma Inc. BetterLife or the Company CSE: BETR OTCQB: BETRF FRA: NPAU today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. Altum, and Pontificia Universidad Católica de Chile have enrolled the first patient in the Phase 1 portion of the Phase 1-2 randomized placebo controlled IN2COVID in COVID-19 patients. The trial tests BetterLifes proprietary inhaled interferon alpha-2b product, AP-003. 